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Tumor can be defined as an abnormal mass of tissue, the growth of which exceeds
and is uncoordinated with that of normal tissue and continues in the same manner after
cessation of the stimuli that have initiated it (1). Control of disseminated tumor growth
by systemically active chemotherapeutic agents remains a major challenge for cancer
chemotherapy despite decades of focused efforts. Although there has been some notable
success with certain forms of cancer, drug therapy has only a limited impact upon the
three major killers: carcinoma of the lung, breast, and colorectal system (2).
Heterocyclic compounds are rich source of diverse physical, chemical and biological
properties (3). Good therapeutic properties of the imidazole related drugs have encourag-
ed medicinal chemists to synthesize a large number of novel chemotherapeutic agents.
Medicinal properties of imidazoles include anticancer, inhibiting b-lactamase, 20-HETE
(20-hydroxy-5,8,11,14-eicosatetraenoic acid) synthase, carboxypeptidase, heme oxyge-
nase, antiaging, anticoagulating, anti-inflammatory, antibacterial, antifungal, antiviral,
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antitubercular, antidiabetic and antimalarial activities (4). Benzimidazoles are heterocyclic
compounds having various biological activities (5), among which albendazole, mebend-
azole and thiabendazole are widely used anthelmintic drugs. Furthermore, benzimidazole
compounds are also reported to possess biological activities such as inhibition of the
angiopoietin receptor TIE-2 and tyrosine kinase receptor VEGFR-2 (vascular endothelial
growth factor receptor-2), antitumor activity, thrombopoietin receptor agonistic activity,
gamma-aminobutyric acid (GABA) agonistic activity, antimicrobial activity, topoisome-
rase inhibition, neuropeptide Y1 receptor antagonistic activity and inhibition of angio-
tensin II. Tetrazoles can act as pharmacophores for the carboxylate group and increase
its utility (6, 7). Angiotensin II blockers often contain tetrazoles such as losartan and
candesartan. A well-known tetrazole is dimethyl thiazolyl diphenyl tetrazolium salt
(MTT), which is used in the MTT assay to quantify the respiratory activity of live cells in
cell cultures, although it kills the cells in the process. Recent observations suggest that
substituted benzoxazoles and related heterocycles possess potential activity with lower
toxicity in the chemotherapeutic approach in man (8). Careful literature survey revealed
that targets containing benzoxazole moiety, either isolated from plants or accessed by
total synthesis, have remarkable biological activities, such as antimicrobial, antihistaminic,
antiparasitic, herbicidal, antiallergic and antihelmintic activities. They were screened for
cytotoxic activity by the MTT assay.
EXPERIMENTAL
Melting points were determined with a digital melting point apparatus (LAB India
MR-VIS, India) and are uncorrected. Elemental analyses were performed on a Perkin-
-Elmer 2400 analyzer (Perkin-Elmer, USA) and were found within  0.4 % of the theore-
tical values. FTIR spectra were recorded on a Shimadzu FT-IR model spectrophotometer
(Japan). 1H NMR spectra were recorded in DMSO on a Bruker AV III 500 MHz (USA)
using TMS as internal standard. Mass spectra were recorded on a JEOL GCmate instru-
ment (Japan). The purity of the compounds was checked by TLC on pre-coated silica gel
G (HF254) aluminium plates (Merck, USA) using chloroform/methanol (4:1) and visua-
lized in a UV chamber.
Compounds 3-(4-(2-methyl-4-oxoquinazolin-3(4H)-yl)phenylamino)propanenitrile (1),
3,3’-(4,4’-sulfonylbis(4,1-phenylene)bis(azanediyl))dipropanenitrile (6), 3,3’-(6-phenyl-
-1,3,5-triazine-2,4-diyl)bis(azanediyl)dipropanenitrile (12) and 3,3,3’,1,3,5-triazine-2,4,6-
-triyl)tris(azanediyl)tripropanenitrile (18) were prepared from primary amine by treat-
ment with acrylonitrile and Triton B following reported literature (9).
Syntheses of benzoxazoles, imidazoles and benzimidazoles. – 3-(4-(2-(benzo[d]oxazol-2-yl)-
-ethylamino)phenyl)-2-methylquinazolin-4(3H)-one (2), 4,4’-sulfonylbis(N-(2-(benzo[d]ox-
azol-2-yl)ethyl)aniline (7), N-bis(2-(benzo[d]oxazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-
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Table I. Physical and analytical data of synthesized compounds




Elemental analysis (calcd./found, %)
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Table II. Spectral data of synthesized compounds
Compd. IR (KBr) (n, cm–1) 1H NMR (DMSO-d6)(d, ppm) MS, m/z (%)
2 3306 (C-H), 2921 (CH2),
1507 (C=N), 3400 (-NH)
2.08 (s, 3H, CH3), 7.53 (s, 12H, Ar-H),
3.34 (s, 2H, CH2), 3.02 (s, 2H, CH2)
395.54 (M-1, 62), 348.98
(21), 207.20 (52), 56.11
(100)
3 3221 (C-H), 2926 (CH2),
1609 (C=N), 3346 (-NH)
6.7–7.5 (m, 8H, Ar-H), 3.37 (s, 2H,
CH2), 2.48 (s, 3H, CH3), 8.2 (s, NH)
346.78 (M+1, 12), 141.11
(100), 215.91 (16), 129.21
(64), 115.15 (52). 105.19
(29)
4 3055 (C-H), 2926 (CH2),
1627 (C=N), 3315 (-NH)
6-6.4 (m, 8H, Ar-H), 3.6 (s, 2H,
CH2-C), 2.9 (s, 2H, CH2), 2.48 (s, 3H,
-N=C-CH3), 8.1 (s, NH benzimidazole)
394.54 (M-1, 70), 294.91
(72), 279.98 (75), 269.23
(78), 206.26 (100)
7 3100 (C-H), 2929 (CH2),
1591 (C=N), 3350 (-NH)
7.31–7.5 (m, 8H, benzoxazole), 7.5
(d, 4H, J = 11.5, Ar-H), 6.57–6.58 (d,
4H, J = 8.5, Ar-H), 3.58 (s, 2H, CH2),
2.89 (s, 2H, -CH2) 7.95 (s, 1H, NH)
537.92 (M-1, 17), 425.06
(6), 126.84 (100), 254.62
(37), 182.86 (52)
8 3085 (C-H), 2928 (CH2),
1634 (C=N), 3421 (-NH)
6.56–6.58 (d, 4H, J = 8.5, Ar-H),
7.42–7.44 (d, 4H, J = 8.5, Ar-H), 3.38
(s, 2H, -CH2-N), 3.8 (s, C-NH), 5.98
(s, 4H, CH2 imidazole ring),
8.2 (s, NH, imidazole)
435.72 (M-1, 6), 423.75
(20), 247.61 (50), 101.76
(100), 139.77 (37)
9 3223 (C-H), 2929 (CH2),
1592 (C=N), 3360 (-NH)
6.58–6.69 (m, 4H, Ar-H), 7.1–7.5
(m, 4H, Ar-H), 3.30 (s, 2H, CH2),
2.80 (s, 2H,CH2), 8.0 (s, 1H, NH
benzimidazole)
535.77 (M-1, 7), 252.77
(15), 148.89 (100), 122.88
(47)
10 3098 (C-H), 3005 (CH2),
1602 (C=N), 3426 (-NH),
1424 (-N=N), 1225
(-N-N=N), 1102 and 1145
(tetrazole ring)
7.5–7.8 (m, 4H, Ar-H), 6.68–.69 (d,
4H, J = 18, Ar-H), 3.38 (s, 2H, -CH2),
2.8 (s, 2H, CH2) 8.3 (s, 1H, NH)
5.7 (s, NH tetrazole)
440.63 (M+, 27), 260.60
(100), 247.61 (77), 300.52
(32)
13 3050 (C-H), 2921 (CH2),
1529 (C=N), 3400 (-NH)
7.5 (s, 12H, Ar-H), 3.4 (s, 2H, CH2),
2.8 (s, 2H, -CH2)
478.76 (M+1, 5), 442.31
(25), 262.25 (74), 182.62
(100), 167.77 (63)
14 3005 (C-H), 2643 (CH2),
1697 (C=N), 3417 (-NH).
3.4 (s, 2H, -CH2), 2.8 (s, 2H, CH2),
5.72 (s, 4H, -CH2 imidazole ring), 8.1
(s, NH, imidazole), 7.5 (s, 8H, Ar-H)
374.56 (M-1, 9), 172.23
(100), 164.67 (42)
15 3057 (CH), 2924 (CH2),
1625 (C=N), 3380 (-NH)
3.42 (s, 2H, CH2), 2.89 (s, 2H, CH2);
4.5 (s, 1H, -NH), 7.45 (s, 12H, Ar-H),
12.33 (s, 1H, -NH benzimidazole)
475.05 (M+, 5), 442.32
(16), 262.26 (37), 182.72
(67), 54.50 (100)
16 3102 (C-H), 2932 (CH2),
1590 (C=N), 3397 (-NH),
1430 (-N=N), 1231
(-N-N=N), 1099 and 1169
(tetrazole ring)
2.5 (s, 2H, CH2), 3.5 (s, 2H, CH2),
4 (s, 1H, NH), 7.3-8.5 (s, 5H, Ar-H),
5.5 (s, 1H, NH tetrazole ring)
378.78 (M-1, 7), 262.26
(19), 247.30 (41), 182.72
(36), 167.79 (100), 121.98
(19)
19 3090 (C-H), 2926 (CH2),
1639 (C=N), 3402 (-NH)
3.58 (s, 2H, CH2), 2.89 (s, 2H, CH2)
7.1–7.6 (m, 8H, Ar-H)
561.10 (M+, 10), 550.32 (8),
518.11 (15), 246.33 (100),
229.36 (25), 213.38 (17),
-4(3H)-one (4), 4,4’-sulfonylbis(N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)aniline (9), N-bis(2-
-(1H-benzo[d]imidazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (15), N-tris(2-1H-
-benzo[d]imidazol-2-yl)ethyl)-1,3,5-triazine-2,4,6-triamine (21).
To a mixture of (3-(4-(2-methyl-4-oxoquinazolin-3(4H)-yl)phenylamino)propaneni-
trile (1) (0.01 mol, 2.13 g), 3,3’-(4,4’-sulfonylbis(4,1-phenylene)bis(azanediyl))dipropan-
enitrile (6) (0.01 mol, 3.54 g) or 3,3’-(6-phenyl-1,3,5-triazine-2,4-diyl)bis(azanediyl)di-
propanenitrile (12) (0.01 mol, 2.93 g) and 3,3,3’,1,3,5-triazine-2,4,6-triyl)tris(azanediyl)tri-
propanenitrile (18) (0.01 mol, 2.85 g) and o-aminophenol (0.01 mol, 1.09 g) or ethyl-
enediamine (0.01 mol, 0.60 g) or o-phenylenediamine (0.01 mol, 1.08 g), 5 mL of conc.
HCl was added and refluxed at 160 °C on an oil bath for ten hours. The hydrochloride
was precipitated after cooling for four hours. The precipitate was filtered and washed
with an ethanol/ether mixture (1:5), suspended in acetone and made alkaline with a
strong ammonia solution. Excess of water was added to liberate the base as a solid. The
solid was filtered, washed with water and recrystallized from methanol to get benzoxa-
zole or imidazole or benzimidazole by reacting the nitriles with ethylenediamine and
o-phenylenediamine, respectively.
Syntheses of tetrazole (4,4’-sulfonylbis(N-(2-(1H-tetrazole-5-yl)ethyl)aniline) (10), N-bis-
(2-1H-tetrazol-5-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (16) and N-tris(2-(1H-tetrazol-
-5-yl)ethyl)-1,3,5-triazine-2,4,6-triamine (22).
To a mixture of compound (3-(4-(2-methyl-4-oxoquinazolin-3(4H)-yl)phenylami-
no)propanenitrile (1) (0.01 mol, 2.13 g), 3,3’-(4,4’-sulfonylbis(4,1-phenylene)bis(azanedi-
yl))dipropanenitrile (6) (0.01 mol, 3.54 g), 3,3’-(6-phenyl-1,3,5-triazine-2,4-diyl)bis(azane-
diyl)dipropanenitrile (12) (0.01 mol, 2.93 g) or 3,3,3’,1,3,5-triazine-2,4,6-triyl)tris(azane-
diyl)tripropanenitrile (18) (0.01 mol, 2.85 g), sodium azide (0.01 mol, 0.65 g), dimethyl-
formamide (10 mL) and NH4Cl (0.1 mol, 5.3 g) was placed in a 100-mL round-bottomed
flask. The content was heated in oil bath for seven hours at 125 °C. The solvent was re-
moved at reduced pressure. The reaction mixture was dissolved in 100 mL distilled wa-
ter and carefully acidified with dil. HCl (1:1) (2 mL) to make solution of pH 2. The solu-
tion was cooled to 5 oC in an ice bath. The product was isolated by filtration, washed
with several portions of water and dried. The crude product was recrystallized from
DMF.
Physicochemical and spectral data for the synthesized compounds are given in Tab-
les I and II. Synthetic routes are presented in Schemes 1–4.
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20 3099 (C-H), 2883 (CH2),
1631 (C=N), 3261 (-NH)
2.5 (s, 2H, CH2), 3.4 (s, 2H, CH2), 6
(s, 1H, NH), 7.9 (s, 1H, NH imidazole)
408.10 (M+, 7), 393.34
(5), 58.71 (100), 201.11
(72), 217.95 (52)
21 3164 (CH), 2930 (CH2),
1634 (C=N), 3411 (-NH)
2.5 (s, 2H, CH2), 3.4 (s, 2H, CH2),
7.5 (s, 12H, Ar-H), 12.53 (s, 1H, -NH
benzimidazole)
558.10 (M+, 5), 63.13
(100), 175.29 (17),
145.73 (45)
22 3205 (C-H), 2939 (CH2),
1655 (C=N), 3408 (-NH),
1404 (-N=N), 1225
(-N-N=N), 1101 and 1174
(tetrazole ring)
2.5 (s, 2H, CH2), 3.4 (s, 2H, CH2)
7.5–8.0 (s, 5H, Ar-H), 5.5 (s, 1H, NH
tetrazole ring)
414.13 (M+, 11), 70.83
(100), 251.43 (32), 373.20
(17), 110.75 (38), 96.81
(58)
258
S. Arulmurugan and H. P. Kavitha: Synthesis and potential cytotoxic activity of some new benzoxazoles, imidazoles, benzimidazoles


































































































The tumor cell growth inhibition activities of the newly synthesized compounds
were assessed in vitro on the human cancer cell line MCF-7 (breast cancer) and HT-29
(colon cancer) obtained from the National Centre for Cell Sciences (NCCS), Pune, India.
5-Fluorouracil (Merck, Germany) was used as a standard.
Cultured cells were trypsinized and resuspended in growth medium. The cells were
seeded at 1  105 cells per well in a 96-well plate and incubated for 24 h in a CO2
incubator. The cells were treated with different concentrations (1, 5, 10, 12.5, 25, 50, 75,
100, 125 and 250 µg mL–1) of test compounds and then incubated for 24 h in the CO2
incubator. To each well, 10 µL of MTT reagent was added and they were again incubated
for 4 h at 37 °C. Each experiment was done in triplicate. The content of each well was
transferred to a different Eppendorf tube and centrifuged at 2000 rpm for 10 minutes.
The pellets obtained were dissolved by adding 200 µL of DMSO and were made up to
2 mL. Absorbance was measured at 550 nm and the % viability was calculated from the
mean absorbance of the test compound in respect to the mean absorbance of the control.
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The IC50 values were reported as mean ± standard deviation of three independent
experiments. One-way analysis of variance (ANOVA) and Student t-test were used to
compare data using the Graph Pad Prism 5.0 software at a 95 % confidence limit.
RESULTS AND DISCUSSION
Chemistry
3-(4-(2-Methyl-4-oxoquinazolin-3(4H)-yl)phenylamino)propanenitrile (1) on treatment
with o-aminophenol, ethylenediamine and o-phenylene diamine yielded the compounds
3-(4-(2-(benzo[d]oxazol-2-yl)ethylamino)phenyl)-2-methylquinazolin-4(3H)-one (2), 3-(4-
-(2-((1H-imidazol-2-yl)ethylamino)phenyl-2-methylquinazolin-4(3H)-one (3) and 3-(4-(2-
-(1H-benzo[d]imidazol-2-yl)ethylamino)phenyl)-2-methylquinazolin-4(3H)-one (4), respec-
tively (Scheme 1). A similar reaction was carried out to synthesize compounds 7-9
(Scheme 2), 14-16 (Scheme 3) and 20-22 (Scheme 4) from compound 3,3’-(4,4’-sulfonyl-
bis(4,1-phenylene)bis(azanediyl))dipropanenitrile (6), 3,3’-(6-phenyl-1,3,5-triazine-2,4-
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-diyl)bis(azanediyl)dipropanenitrile (12) and 3,3,3’,1,3,5-triazine-2,4,6-triyl)tris(azane-
diyl)tripropanenitrile (18) respectively. The structures of the compounds were confirmed
by IR, 1H NMR, mass spectra and elemental analysis.
Benzoxazoles (3-(4-(2-(benzo[d]oxazol-2-yl)ethylamino)phenyl)-2-methylquinazolin-
-4(3H)-one (2), 4,4’-sulfonylbis(N-(2-(benzo[d]oxazol-2-yl)ethyl)aniline) (7), N-bis(2-(ben -
zo[d]oxazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (13) and N-tris(2-(benzo[d]oxa-
zol-2-yl)ethyl)-1,3,5-triazine-2,4,6-triamine (19) were prepared by treating compounds 1,
6, 12 and 18 with o-aminophenol in the presence of conc. HCl at 160 °C. In general, infra-
red spectral data of all benzoxazoles (2, 7, 13, 19) revealed bands at 3350–3402 (-NH),
2921–2929 (CH2), 1507–1639 (C=N) and 3050–3306 cm–1 (CH). The 1H NMR spectrum of
the compounds showed a singlet at d 3.4–3.58 ppm which can be assigned to methylene
protons. A multiplet at d 7.1–7.6 ppm was attributed to aromatic protons. A singlet was
observed for the –NH proton at d 7.95 ppm. Compound 2 showed a singlet at d 2.08 ppm
for CH3 protons. Molecular ion peaks were observed at m/z 395.54, 537.92, 478.76 and
561.10 for compounds 2, 7, 13, 19, respectively.
Imidazoles (3-(4-(2-((1H-imidazol-2-yl)ethylamino)phenyl-2-methylquinazolin-4(3H)-one
(3), 4,4’-sulfonylbis(N-(1H-imidazol-2-yl)ethylaniline (8), N-bis(2-1H-imidazol-2-yl)eth-
yl)-6-phenyl-1,3,5-triazine-2,4-diamine (14), and N-tris(2-1H-imidazol-2-yl)ethyl)-1,3,5-
-triazine-2,4,6-triamine (20) were prepared by treating compounds 1, 6, 12 and 18 with
ethylenediamine in the presence of conc. HCl at 160 °C. The molecular ion peaks ob-
served at m/z 346.78, 435.72, 374.56 and 408.10 for compounds 3, 8, 14 and 20 confirm the
molecular mass of the compounds. The IR spectrum of imidazoles (3, 8, 14 and 20)
showed characteristic bands at 3050–3223 (CH), 2921–2926 (CH2), 1507–1639 (C=N) and
3315–3402 cm–1 (-NH). The 1H NMR spectra of all imidazole compounds showed
singlets at d 2.5 and 3.4 ppm which can be assigned to methylene protons. Compound 3
showed a multiplet at d 6.7–7.5 ppm, which may be assigned to aromatic protons. The
three singlets appearing at d 8.2, 3.37 and 2.48 ppm are attributed to NH (imidazole),
methylene and methyl protons, respectively.
Benzimidazoles (3-(4-(2-(1H-benzo[d]imidazol-2-yl)ethylamino)phenyl)-2-methylquin-
azolin-4(3H)-one (4), 4,4’-sulfonylbis(N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)aniline (9),
N-bis(2-(1H-benzo[d]imidazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (15), N-tris(2-
1H-benzo[d]imidazol-2-yl)ethyl)-1,3,5-triazine-2,4,6-triamine (21) were prepared by treat-
ing compounds 1, 6, 12 and 18 with o-phenylenediamine in the presence of conc. HCl at
160 °C. Molecular ion peaks were obtained at m/z 394.54, 535.77, 475.05 and 558.10 for
compounds 4, 9, 15 and 21, respectively. The IR spectra of benzimidazoles showed charac-
teristic bands at 3055–3223 (CH), 2924–2930 (CH2), 1592–1634 (C=N) and 3315–3411 cm–1
(-NH). The 1H NMR spectrum of all the four benzimidazole compounds showed singlets
at d 3.3 and d 2.9 ppm, which can be assigned to methylene protons. The strong peaks
observed as a singlet at d 12.33 to 12.53 ppm are due to NH proton of the benzimidazole
ring of compounds 15 and 21, respectively. Compound 4 showed a multiplet at d 6-6.4 ppm,
which can be assigned to aromatic protons. The methyl protons attached to the quin-
azoline ring showed a singlet at d 2.48 ppm. The singlet appearing at d 8.1 ppm can be
attributed to NH (benzimidazole) protons.
Compounds 4,4’-sulfonylbis(N-(2-(1H-tetrazole-5-yl)ethyl)aniline (10), N-bis(2-1H-
tetrazol-5-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (16), and N-tris(2-(1H-tetrazol-5-
yl)ethyl)-1,3,5-triazine-2,4,6-triamine (22) were prepared by treating 3,3’-(4,4’-sulfonyl-
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bis(4,1-phenylene)bis(azanediyl))dipropanenitrile (6), 3,3’-(6-phenyl-1,3,5-triazine-2,4-diyl)
bis(azanediyl)dipropanenitrile (12) and 3,3,3’,1,3,5-triazine-2,4,6-triyl)tris(azanediyl)tri-
propanenitrile (18) with NaN3 and NH4Cl (Schemes 2-4). The infrared spectral data of
all the three tetrazoles (10, 16 and 22) revealed bands at m 3397–3426 (-NH), 2932–3005
(CH2), 1590–1655 (C=N), 3098–3205 (CH), 1404–1430 (N=N), 1225–1231 (N-N=N) and
1099–1174 (tetrazole ring) cm–1. The 1H NMR spectrum of the compounds showed a sin-
glet at d 2.5–2.8 and 3.38–3.5 ppm, which can be assigned to methylene protons. The sin-
glet observed at d 5.5–5.7 ppm was due to the –NH protons of the tetrazole ring. Molec-
ular ion peaks obtained at m/z 440.63, 378.78 and 414.13 for compounds 10, 16 and 22
confirm the molecular weight of the compounds.
Cytotoxicity screening
Induction of cell death or inhibition of cell proliferation is an important property for
chemotherapeutic agents. The cytotoxic effect of compounds 2–4, 7–10, 13–16 and 19–22
was evaluated by measuring the level of cell proliferation after incubation of the cells
with the test samples using the MTT colorimetric assay (10). The results are expressed as
percentage of cell proliferation compared to the cell control (cells treated with vehicle,
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Table III. Cytotoxic activity of newly synthesized compounds

















5 FU 6.2 5.5
IC50 – concentration required to inhibit cell viability by 50 %:
Control: DMSO.
DMSO 0.1 %). The results of IC50 values of MCF-7 (breast cancer) and HT-29 (colon can-
cer) of test compounds are presented in Table III.
It is evident from the study that all the heterocyclic compounds synthesized in the
present work had a cytotoxic effect on the tested cell lines. It is worth noting that com-
pounds 9, 13, 15 and 21 exhibit IC50 values comparable to the standard drug 5-flurour-
acil. From the results of the study, it is inferred that among the new heterocyclic com-
pounds synthesized in the present research work, compounds with benzimidazole and
benzoxazole moieties exhibit good cytotoxic activity. It is interesting to note that among
the four benzimidazole compounds synthesized (4, 9, 15 and 21), three compounds, viz.,
4,4’-sulfonylbis(N-(2-(1H-benzo[d]imidazol-2-yl)ethyl)aniline (9), N-bis(2-(1H-benzo[d]imi-
dazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (15) and N-tris(2-1H-benzo[d]imi-
dazol-2-yl)ethyl)-1,3,5-triazine-2,4,6-triamine (21) exhibit potent cytotoxicity with IC50
values of 5.7 (MCF-7), 5.2 (HT-29), 7.22 (MCF-7), 5.9 (HT-29) 6.0 µg mL–1 (MCF-7), and
5.5 µg mL–1 (HT-29), respectively. Among the four benzoxazole derivatives (2, 7, 13 and
19), N-bis(2-(benzo[d]oxazol-2-yl)ethyl)-6-phenyl-1,3,5-triazine-2,4-diamine (13), shows
potent cytotoxic activity against the two cancer cell lines taken for the study. The least
potency was shown by compounds 10, 16 and 22 containing tetrazole moiety.
From the data of cytotoxic activity, compounds 9, 15 and 21 were found to possess
promising cytotoxic activity. This activity of the compounds may be due to the presence
of dapsone, triazine and benzimidazole moieties. The remarkable antiproliferative acti-
vity of compound 13 may due to the presence of triazine and benzoxazole moieties.
CONCLUSIONS
In the present study, syntheses of some new benzimidazoles, benzoxazoles, imida-
zoles and tetrazoles is described. All the compounds were evaluated for cytotoxic activi-
ty. Benzimidazoles 9, 13, 15 and 21 and benzoxazole 13 were found to be the most active
compounds with a promising cytotoxic activity. It can be deduced from the results that
benzimidazole and benzoxazole moiety can create potent cytotoxic compounds, where-
as imidazole and tetrazole compounds show lower cytotoxic effects. Further studies and
structural modifications are needed to increase the cytotoxic activity.
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